European Federation of Pharmaceutical Industries and Associations (EFPIA)

Registration on EU Transparency Register

Website

Goals / Remit

EFPIA operates as the representative organisation of the research based pharmaceutical industry in Europe. The aim of the Federation, which has no profit-making purpose, is to promote pharmaceutical discovery and development in Europe and to promote a European regulatory environment, which facilitates innovative medicinal products to the market in order to improve human health worldwide.

In addition, EFPIA pursues a mainly scientific aim, ensuring and promoting the technological and economic development of the pharmaceutical industry in Europe. EFPIA’s activities extend to all matters of common interest to its members. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.

EFPIA has developed Guidance for its members and it is available on its website.

Issues

Any health or pharmaceutical policy stemming from the European institutions, such as life sciences strategy, industrial policy, European Semester, Horizon Europe Research Programme, HTA policy, IP policy, One Health Approach to tackle AMR, pharmaceutical, orphan and paediatrics legislation, COVID-19 outbreak measures, etc. EFPIA also follows ongoing trade negotiations and legislative files when relevant to the innovative pharmaceutical industry (such as Water Framework Directive, Welfare of animals in scientific testing etc).

Lobbyists with EP accreditation

Complementary information

In 2019, EFPIA’s Team was constituted of 49 employees, including 4 dedicated to Vaccines and 3 dedicated to EBE, both 'specialised groups' within EFPIA. As these groups were in 2019 registered separately, staff dedicated to their activities are not included in the EFPIA reporting.
EFPIA employees that are not involved in activities within scope of the Register or only occasionally i.c. spending less than 10% of their work time with EU Institutions are not included in the number of persons.

Numbers show the situation per 31 December 2019 for the financial year 2019.

Person in charge of EU relations

Person with legal responsibility

Category

II - In-house lobbyists and trade/professional associations

Subcategory

Trade and business organisations

Affiliation

BIAC
British Chamber of Commerce
DIA
EACD
EAPM
EPC
FAIB
Friends of Europe
Kangaroo Group
TOPRA
European Risk Forum
THE EUROPEAN HOUSE - AMBROSETTI

Lobbying costs

4,651,809€

Procurement from EU institutions

0 €

Grants from EU institutions

0 €

Total budget

0 €

Total public financing

0 €

Other financial information

EFPIA recommends that, along with EFPIA, each of its constituent entities – including corporate members, member associations and members of specialised groups – register in their individual capacity.
EFPIA, has developed a Guidance to its members. The Guidance aims at supporting consistent and transparent reporting among EFPIA members, and will be made public. The EFPIA Guidance followed the provisions in the renewed Interinstitutional Agreement between the European Parliament and the EU Commission, and builds on the recommendations of the Joint Transparency Register Secretariat.
Information included in the EFPIA Registration complies with the EFPIA Guidance. EFPIA will provide detailed information upon request.
The EFPIA specialised groups have registered separately (in year 2019): EBE with public ID number 768792210017-73 and Vaccines Europe (VE) with public ID number 53073567234-18. Since specialised groups have no legal responsibility, their registration is under the legal responsibility of EFPIA. However, EBE and VE will be registered as separate “subsidiaries”, with cross-referencing links.
Constituent entities that are not included in the EU “Transparency Register” shall not be part of EFPIA delegations interacting with the EU Commission / EP.
€

There are no notes attached to this organisation.

High-level groups

Consultative committees

Expert groups (European Commission)

Multistakeholder expert group to support the application of Regulation (EU) 2016/679#E03537 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3537 #Member #C#Expert group on follow-up activities related to Corporate Responsibility in the field of Pharmaceuticals #E02558 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2558 #Member #C#eHealth Stakeholder Group#E02769 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2769 #Member #C#Technical Expert Group for the implementation of the Directive on the protection of animals used for scientific purposes#E02551 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2551 #Member #C#Medical Device Coordination Group#X03565 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3565 #Observer #C#04 - Post-Market Surveillance and Vigilance (PMSV)#02 - Standards#07 - New Technologies#06 - Borderline and Classification (B&C)#03 - Clinical Investigation and Evaluation (CIE)#Competent Authorities' Expert Group on the protection of animals used for scientific purposes#E02539 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2539 #Observer #C#European Alcohol and Health Forum#E02224 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2224 #Member #C#Consultation Forum on Access and benefit sharing (ABS)#E03396 #http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=3396 #Member #C

Intergroups (European Parliament)

None

Industry forums (European Parliament)

None

Complementary information

EFPIA covers regularly the committee debates in the European Parliament and attends public hearings, conferences, roundtables and similar that are important to the industry. EFPIA also meets on a regular basis Members of the European Parliament and assistants to facilitate the dialogue with the policy makers.
EFPIA has also regular interaction with the European Commission services, including DG GROW, DG SANTE, DG RTD, DG TRADE, DG ENV, etc.
In addition, EFPIA is also is
Accredited stakeholder association to ECHA
Observer to the EU Commission NCP on Dir 2010/63/EU (DG ENV)
Observer to the EU Commission chemicals working group (DG ENV)
Member of the EPAA (DG GROW)

Meetings with European Commission

76 meetings found.

The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

08 May 2020 - Commissioner Thierry Breton - Video call with Pharmaceutical Industrial Associations, the European Medicines Agency and the European Centre for Disease Prevention and Control, to discuss Possible shortages of medicines and medical devices for the Covid-19 outbreak (DG Internal Market)

08 May 2020 - Commissioner Stella Kyriakides - Video call with Pharmaceutical Industrial Associations, the European Medicines Agency and the European Centre for Disease Prevention and Control, to discuss Possible shortages of medicines and medical devices for the Covid-19 outbreak (DG Health and Food Safety)

29 Apr 2020 - Commissioner Stella Kyriakides - Video call with Pharmaceutical Industrial Associations, the European Medicines Agency and the European Centre for Disease Prevention and Control, to discuss Possible shortages of medicines and medical devices for the Covid-19 outbreak (DG Health and Food Safety)

29 Apr 2020 - Commissioner Thierry Breton - Video call with Pharmaceutical Industrial Associations, the European Medicines Agency and the European Centre for Disease Prevention and Control, to discuss Possible shortages of medicines and medical devices for the Covid-19 outbreak (DG Internal Market)

27 Oct 2017 - Head Of Task Force Michel Barnier - Meeting with the Task Force for the Preparation and Conduct of the Negotiations with the United Kingdom under Article 50 TEU (DG Task Force for Relations with the United Kingdom)